Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Second primary malignancies in lymphoma patients.

T Takenaka, C Konda, T Sakano

    Japanese Journal of Clinical Oncology
    |June 1, 1985
    PubMed
    Summary

    This study found that female Hodgkin's disease patients had a higher risk of developing second cancers, particularly stomach cancer. Non-Hodgkin's lymphoma patients did not show this increased risk.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).

    Annals of oncology : official journal of the European Society for Medical Oncology·2018
    Same author

    Coping strategies and risk of cardiovascular disease incidence and mortality: the Japan Public Health Center-based prospective Study.

    European heart journal·2016
    Same author

    Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2015
    Same author

    A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2015
    Same author

    Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.

    Annals of oncology : official journal of the European Society for Medical Oncology·2015
    Same author

    Development and Validation of LC-MS/MS Assay for the Quantification of Progesterone in Rat Plasma and its Application to Pharmacokinetic Studies.

    Drug research·2014

    Area of Science:

    • Oncology
    • Hematology
    • Cancer Epidemiology

    Background:

    • Patients treated for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) may be at increased risk for secondary malignancies.
    • Understanding the patterns of these second cancers is crucial for long-term patient management and survivorship.

    Purpose of the Study:

    • To investigate the incidence and types of second malignancies in patients with HD and NHL.
    • To compare the observed rates of second cancers with expected rates based on population data.
    • To analyze potential differences in second cancer risk between sexes and across different lymphoma types.

    Main Methods:

    • Retrospective analysis of 74 HD and 407 NHL patients treated at the National Cancer Center Hospital for over one year.
    • Data collection on second malignancy development, cancer type, patient demographics, and treatment history.

    Related Experiment Videos

  • Statistical comparison of observed versus expected second cancer incidence using age-adjusted person-years.

    • Main Results:

    • Fifteen out of 481 patients developed a second malignancy.
    • Gastric cancer was the most common second cancer (10 cases); acute nonlymphocytic leukemia was not observed.
    • Female HD patients showed a significantly higher observed incidence of all second cancers and stomach cancer compared to expected rates (p < 0.005).
    • No significant sex-based differences in second cancer incidence were found in NHL patients.
    • No significant differences in second malignancy rates were observed based on treatment modality across any group.

    Conclusions:

    • Female patients with a history of Hodgkin's disease exhibit an elevated risk for developing secondary cancers, notably gastric cancer.
    • The risk profile for second malignancies appears distinct between Hodgkin's disease and non-Hodgkin's lymphoma.
    • Further research is warranted to elucidate the specific mechanisms driving increased second cancer risk in certain lymphoma patient subgroups.